| Publications on Health Policy subjects | |||
|---|---|---|---|
The Health Policy Division produces a wide range of publications in
every field of its activities. Here you find the complete list of
available books for each subject. |
|||
|
| |||
Guide
to the preparation, use and quality assurance of blood components - 13th
edition (2007) |
Guide
to the preparation, use and quality assurance of blood components - 12th
edition (2006) |
||
|
|
|||
|
|
Guide
to the preparation, use and quality assurance of blood components - 10th
edition (2004) |
||
|
|
|||
Guide
to the preparation, use and quality assurance of blood components - 9th
edition (2003) |
|
||
Pathogen
inactivation of labile blood products (2001)The selection of donors and screening of donated blood and plasma have greatly diminished the risk of blood products transmitting viral or other infectious agents. The safety of stable plasma-derived products has been further improved by the inclusion of virus inactivation steps into the manufacturing, by which transfusion-relevant enveloped viruses as well as some non-enveloped viruses are reliably eliminated. But because of their cytotoxicity, these methods cannot be applied to cellular blood products. The safety of cellular blood products has been increased by the introduction of prestorage leukocyte depletion and nucleic acid amplification tests for certain viruses. However, since these methods have their limits, a small but significant infectious risk cannot be excluded today. Moreover, newly emerging infectious agents have been described, and uncertainties about their pathogenicity and their mode of transmission fostering anxieties as to the safety of labile blood products. Methods aimed at the inactivation of pathogens in labile blood products have been developed in recent years. Investigations into some technologies are at an advanced preclinical or already in clinical stages. Evidently, the use of such procedures raises a number of issues, including efficacy, the damage inflicted to labile blood products, the toxicity for patients, and the cost-benefit ratio. In the foreseeable future, national blood transfusion services and health authorities will be faced with this development and will have to consider the introduction of these methods. The report summarises the current information available on these pathogen inactivation procedures. |
|||
|
|
|||
|
The collection and use of human blood and plasma
in Europe - Report prepared by Prof. Dr. W. G. Van Aken (1998) |
The collection
and use of human blood and plasma in the non-European Union Council of
Europe member states in 1995 (1998) |
||
|
|
|||
Blood
transfusion: half a century of contribution by the Council of Europe
(1998) |
Blood
transfusion in Europe: a white paper. Safe and sufficient blood in Europe
(1998) |
||
|
|
|||
|
Activities of blood bank in the Council of Europe member
states related to bone marrow transplantations (1997) |
Additional
Protocol to the European Agreement on the Exchanges of Blood-Grouping
Reagents (ETS 111) (1998) |
||
|
|
|||
| European
Agreement on the Exchange of Blood-Grouping Reagents (ETS 39) (1998) |
|||
|
|
|||
Guide to safety and quality assurance for organs,
tissues and cells –2nd Edition (2004)
This
Guide includes standards for procurements, preservation, processing and
distribution of organs, tissues and cells. It is the first international
text on this topic adopted by Health Authorities. |
Guide to safety and quality assurance for organs, tissues
and cells – 1st Edition (2002) This Guide includes standards for procurements, preservation, processing and distribution of organs, tissues and cells. It is the first international text on this topic adopted by Health Authorities. |
||
|
|
|||
| Additional
Protocol to the Convention on Human Rights and Biomedicine concerning
Transplantation of Organs and Tissues of Human Origin - Strasbourg,
24.I.2002 (ETS N° 186) (2002) |
|||